CR
CRIS.US Curis Inc
- Market cap
- USD 2.97M
- P/E
- 0.4x
- P/B
- 0.30x
- ROE
- -2,137.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRIS.US undervalued?
Graham numberThe Graham number of Curis Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Curis Inc fundamental analysis
No fundamental analysis for Curis Inc yet.
Curis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDA…
Full company profileCuris Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Curis Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.53M | 9.90M | 10.4M | 10.0M | 10.8M | 10.6M | 10.2M | 10.0M | 10.9M | 9.44M | - |
| Gross Profit | 7.13M | 9.40M | 9.87M | 9.50M | 10.3M | 10.1M | 9.91M | 10.0M | 10.8M | 9.40M | - |
| Operating Income | -58.0M | -49.8M | -29.3M | -24.4M | -24.9M | -42.1M | -53.0M | -48.3M | -44.5M | -32.9M | -40.3M |
| EBITDA | -57.4M | -49.1M | -28.5M | -27.2M | -24.7M | -40.8M | -52.8M | -48.3M | -42.6M | -5.23M | -57.2M |
| Net Income | -60.4M | -53.3M | -32.6M | -32.1M | -29.9M | -45.4M | -60.3M | -47.4M | -43.4M | -7.58M | -54.5M |
| EPS | -910 | -3,575 | -393 | -387 | -246 | -198 | -13 | -179 | -138 | -12 | -13 |
| Balance Sheet | |||||||||||
| Total Assets | 57.8M | 73.8M | 37.4M | 35.1M | 204M | 162M | 109M | 77.3M | 41.3M | 20.0M | 18.8M |
| Total Liabilities | 28.5M | 49.8M | 41.9M | 69.0M | 73.7M | 71.6M | 62.3M | 57.6M | 47.3M | 14.5M | 16.2M |
| Shareholders' Equity | 29.3M | 24.0M | -4.50M | -33.9M | 131M | 90.7M | 46.6M | 19.7M | -6.00M | 5.46M | 2.55M |
| Cash & Short-term Investments | 44.5M | 60.2M | 24.3M | 20.5M | 168M | 116M | 85.6M | 56.3M | 20.0M | 5.06M | 5.01M |
| Total Debt | 19.9M | 41.6M | 35.5M | 166K | 7.66M | 5.04M | 6.74M | 2.79M | 2.95M | 1.62M | 740K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.8M | -48.4M | -30.1M | -26.2M | -25.7M | -37.6M | -54.3M | -38.4M | -39.6M | -27.2M | -32.5M |
| Capital Expenditure | 329K | 188K | 85.0K | 41.0K | 677K | 416K | 416K | 416K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -36.1M | -48.5M | -30.2M | -26.2M | -26.4M | -37.6M | -54.8M | -38.4M | -39.6M | -27.2M | -32.5M |
| Ratios | |||||||||||
| ROE | -206.4% | -222.2% | - | - | -22.9% | -50.1% | -129.6% | -241.0% | - | -138.8% | -2,137.7% |
| ROA | -104.6% | -72.2% | -87.2% | -91.6% | -14.6% | -28.0% | -55.4% | -61.4% | -105.1% | -38.0% | -290.1% |
| Net Profit Margin | -802.6% | -538.7% | -312.4% | -321.3% | -276.0% | -426.7% | -593.6% | -473.0% | -397.8% | -80.3% | - |
| Debt to Equity | 0.68x | 1.73x | - | - | 0.06x | 0.06x | 0.14x | 0.14x | - | 0.30x | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Curis Inc dividends
Curis Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jul 6, 2026.
Who owns Curis Inc
- Insiders 8.18%
- Institutions 10.17%
- Public & others 81.65%
- Shares outstanding 6.68M
- Free float 1.99M
Top funds holding CRIS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 13.9K | 0.21% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.79K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.65K | 0.02% | 0.00% | Sep 2026 |
| Guggenheim Active Allocation Fund | 1.00 | 0.00% | -50.00% | Aug 2026 |
Top institutions holding CRIS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Stonepine Capital Management Llc | 3.31M | 49.59% | -11.12% | Jun 2026 |
| Nantahala Capital Management, LLC | 1.98M | 29.63% | -1.06% | Jun 2026 |
| Cable Car Capital LLC | 1.33M | 19.96% | 0.00% | Jun 2026 |
| CM Management, LLC | 550K | 8.23% | +266.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 504K | 7.55% | +98.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 344K | 5.15% | -8.14% | Jun 2026 |
| Geode Capital Management, LLC | 293K | 4.39% | +74.12% | Jun 2026 |
| M28 Capital Management LP | 285K | 4.27% | 0.00% | Jun 2026 |
| F.L.Putnam Investment Management | 246K | 3.68% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 142K | 2.13% | -61.29% | Jun 2026 |
| XTX Topco Ltd | 108K | 1.62% | 0.00% | Jun 2026 |
| Sphera Funds Management Ltd. | 99.0K | 1.48% | -95.04% | Jun 2026 |
| Northern Trust Corp | 95.9K | 1.44% | +813.74% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 61.7K | 0.92% | 0.00% | Jun 2026 |
| BlackRock Inc | 53.3K | 0.80% | -0.28% | Jun 2026 |
| Maverick Capital Ltd | 49.6K | 0.74% | 0.00% | Jun 2026 |
| State Street Corp | 21.0K | 0.32% | 0.00% | Jun 2026 |
| Franklin Street Advisors Inc. | 20.0K | 0.30% | 0.00% | Jun 2026 |
| LPL Financial Corp | 15.0K | 0.22% | -37.54% | Jun 2026 |
| Dauntless Investment Group, LLC | 10.0K | 0.15% | -98.48% | Jun 2026 |
Curis Inc company profile
- Company name
- Curis Inc
- Ticker
- CRIS.US
- Exchange
- USA Stocks
- Listed since
- Aug 1, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- Building C, Lexington, MA, United States, 02421
- Phone
- 617 503 6500
- Website
- curis.com
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Curis Inc management
6- Mr. James E. DentzerPresident, CEO, Secretary, Treasurer & Director · born 1967
- Ms. Diantha Duvall C.P.A., M.B.A.CFO and Principal Financial & Accounting Officer · born 1972
- Dr. Jonathan B. Zung Ph.D.Chief Development Officer · born 1965
- Mr. Mark W. NoelVice President of Technology Management & Intellectual Property · born 1959
- Ms. Rachel BlasbalgSenior Director of Human Resources
- Dr. Ahmed M. Hamdy M.D.Chief Medical Officer · born 1965